Treatment resistance in pancreatic and biliary tract cancer: molecular and clinical pharmacology perspectives

References

• Banales JM, Marin JJG, Lamarca A, et al. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol. 2020;17:557–588. doi: 10.1038/s41575-020-0310-z
   PubMed Web of Science ®Google Scholar
• Surveillance, Epidemiology, and End Results (SEER), Program populations (1969-2020) National Cancer Institute, DCCPS, Surveillance Research program. Cancer of the liver and intrahepatic bile duct - Cancer stat facts [internet]. SEER. 2022 [cited 2023 Oct 30]. Available from: https://seer.cancer.gov/statfacts/html/livibd.html
   Google Scholar
• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424. doi: 10.3322/caac.21492
   PubMed Web of Science ®Google Scholar
• Rawla P, Sunkara T, Gaduputi V. Epidemiology of pancreatic cancer: global trends, etiology and risk factors. World J Oncol. 2019;10:10–27. doi: 10.14740/wjon1166
   PubMedGoogle Scholar
• Oh D-Y, Ruth HA, Qin S, et al. Durvalumab plus Gemcitabine and cisplatin in advanced biliary tract cancer. NEJM Evid. 2022;1:EVIDoa2200015.
   PubMedGoogle Scholar
• Oh D-Y, He AR, Qin S, et al. 78P updated overall survival (OS) from the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin (+ GC) in patients (pts) with advanced biliary tract cancer (BTC). Ann Oncol. 2022;33:S1462–S1463. doi: 10.1016/j.annonc.2022.10.114
   Google Scholar
• Kelley RK, Ueno M, Yoo C, et al. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023;401:1853–1865. doi: 10.1016/S0140-6736(23)00727-4
   PubMed Web of Science ®Google Scholar
• Abou-Alfa GK, Sahai V, Hollebecque A, et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. Lancet Oncol. 2020;21:671–684.
   PubMed Web of Science ®Google Scholar
• Vogel A, Sahai V, Hollebecque A, et al. O-2 pemigatinib for previously treated locally advanced or metastatic cholangiocarcinoma: final results from FIGHT-202. Ann Oncol. 2022;33:S379. doi: 10.1016/j.annonc.2022.04.443
   Web of Science ®Google Scholar
• Goyal L, Meric-Bernstam F, Hollebecque A, et al. Futibatinib for FGFR2-rearranged intrahepatic cholangiocarcinoma. N Engl J Med. 2023;388:228–239. doi: 10.1056/NEJMoa2206834
   PubMed Web of Science ®Google Scholar
• Javle M, Roychowdhury S, Kelley RK, et al. Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study. Lancet Gastroenterol Hepatol. 2021;6:803–815. doi: 10.1016/S2468-1253(21)00196-5
   PubMed Web of Science ®Google Scholar
• Abou-Alfa GK, Macarulla T, Javle MM, et al. Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIdhy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2020;21:796–807. doi: 10.1016/S1470-2045(20)30157-1
   PubMed Web of Science ®Google Scholar
• Harding JJ, Fan J, Oh D-Y, et al. Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study. Lancet Oncol. 2023;24:772–782. doi: 10.1016/S1470-2045(23)00242-5
   PubMed Web of Science ®Google Scholar
• Knox JJ, Lee CL, O’Kane G Targets and resistance mechanisms in biliary tract cancers. ASCO Dly News [Internet]. [cited 2023 Oct 5]. Available from: https://dailynews.ascopubs.org/do/10.1200/ADN.23.201274/full
   Google Scholar
• Cho SM, Esmail A, Raza A, et al. Timeline of FDA-Approved targeted therapy for Cholangiocarcinoma. Cancers (Basel). 2022;14:2641. doi: 10.3390/cancers14112641
   PubMed Web of Science ®Google Scholar
• Lamarca A, Palmer DH, Wasan HS, et al. Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial. Lancet Oncol. 2021;22:690–701. doi: 10.1016/S1470-2045(21)00027-9
   PubMed Web of Science ®Google Scholar
• Yoo C, Kim K, Jeong JH, et al. Liposomal irinotecan plus fluorouracil and leucovorin versus fluorouracil and leucovorin for metastatic biliary tract cancer after progression on gemcitabine plus cisplatin (NIFTY): a multicentre, open-label, randomised, phase 2b study. Lancet Oncol. 2021;22:1560–1572. doi: 10.1016/S1470-2045(21)00486-1
   PubMed Web of Science ®Google Scholar
• Vogel A, Wenzel P, Folprecht G, et al. 53MO nal-IRI and 5-FU/LV compared to 5-FU/LV in patients with cholangio- and gallbladder carcinoma previously treated with gemcitabine-based therapies (NALIRICC – AIO-HEP-0116). Ann Oncol. 2022;33:S563–S564. doi: 10.1016/j.annonc.2022.07.081
   PubMed Web of Science ®Google Scholar
• Ying J, Chen J. Combination versus mono-therapy as salvage treatment for advanced biliary tract cancer: a comprehensive meta-analysis of published data. Crit Rev Oncol Hematol. 2019;139:134–142. doi: 10.1016/j.critrevonc.2019.01.001
   PubMed Web of Science ®Google Scholar
• Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364:1817–1825.
   PubMed Web of Science ®Google Scholar
• Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-Paclitaxel plus Gemcitabine. N Engl J Med. 2013;369:1691–1703.
   PubMed Web of Science ®Google Scholar
• Wainberg ZA, Melisi D, Macarulla T, et al. NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial. Lancet. 2023 [cited 2023 Oct 5]. Available from: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)01366-1/fulltext
   PubMed Web of Science ®Google Scholar
• Portal A, Pernot S, Tougeron D, et al. Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort. Br J Cancer. 2015;113:989–995. doi: 10.1038/bjc.2015.328
   PubMed Web of Science ®Google Scholar
• Chung MJ, Kang H, Kim HG, et al. Multicenter phase II trial of modified FOLFIRINOX in gemcitabine-refractory pancreatic cancer. World J Gastrointest Oncol. 2018;10:505–515. doi: 10.4251/wjgo.v10.i12.505
   PubMed Web of Science ®Google Scholar
• Gill S, Ko Y-J, Cripps C, et al. PANCREOX: a randomized phase III study of Fluorouracil/Leucovorin with or without oxaliplatin for second-line advanced pancreatic cancer in patients who have received gemcitabine-based chemotherapy. J Clin Oncol. 2016;34:3914–3920. doi: 10.1200/JCO.2016.68.5776
   PubMed Web of Science ®Google Scholar
• Wang-Gillam A, Li C-P, Bodoky G, et al. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. Lancet. 2016;387:545–557. doi: 10.1016/S0140-6736(15)00986-1
   PubMed Web of Science ®Google Scholar
• Golan T, Hammel P, Reni M, et al. Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. N Engl J Med. 2019;381:317–327. doi: 10.1056/NEJMoa1903387
   PubMed Web of Science ®Google Scholar
• Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007;25:1960–1966. doi: 10.1200/JCO.2006.07.9525
   PubMed Web of Science ®Google Scholar
• Doebele RC, Drilon A, Paz-Ares L, et al. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials. Lancet Oncol. 2020;21:271–282. doi: 10.1016/S1470-2045(19)30691-6
   PubMed Web of Science ®Google Scholar
• Hong DS, DuBois SG, Kummar S, et al. Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials. Lancet Oncol. 2020;21:531–540. doi: 10.1016/S1470-2045(19)30856-3
   PubMed Web of Science ®Google Scholar
• Marabelle A, Le DT, Ascierto PA, et al. Efficacy of Pembrolizumab in patients with noncolorectal high microsatellite Instability/Mismatch repair–deficient cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol. 2020;38:1–10. doi: 10.1200/JCO.19.02105
   PubMed Web of Science ®Google Scholar
• Leroux C, Konstantinidou G. Targeted therapies for pancreatic cancer: overview of current treatments and new opportunities for personalized oncology. Cancers (Basel). 2021;13:799. doi: 10.3390/cancers13040799
   PubMed Web of Science ®Google Scholar
• Zheng H-C. The molecular mechanisms of chemoresistance in cancers. Oncotarget. 2017;8:59950–59964. doi: 10.18632/oncotarget.19048
   PubMed Web of Science ®Google Scholar
• Wu C-E, Pan Y-R, Yeh C-N, et al. Targeting P53 as a future strategy to overcome gemcitabine resistance in biliary tract cancers. Biomolecules. 2020;10:1474. doi: 10.3390/biom10111474
   PubMed Web of Science ®Google Scholar
• Sanchon-Sanchez P, Briz O, Macias RIR, et al. Evaluation of potential targets to enhance the sensitivity of cholangiocarcinoma cells to anticancer drugs. Biomed Pharmacother Biomed Pharmacother. 2023;168:115658. doi: 10.1016/j.biopha.2023.115658
   PubMed Web of Science ®Google Scholar
• Zeekpudsa P, Kukongviriyapan V, Senggunprai L, et al. Suppression of NAD(P)H-quinone oxidoreductase 1 enhanced the susceptibility of cholangiocarcinoma cells to chemotherapeutic agents. J Exp Clin Cancer Res CR. 2014;33:11. doi: 10.1186/1756-9966-33-11
   PubMed Web of Science ®Google Scholar
• Tannapfel A, Sommerer F, Benicke M, et al. Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma. Gut. 2003;52:706–712. doi: 10.1136/gut.52.5.706
   PubMed Web of Science ®Google Scholar
• Peng J, Fang S, Li M, et al. Genetic alterations of KRAS and TP53 in intrahepatic cholangiocarcinoma associated with poor prognosis. Open Life Sci [Internet]. 2023;18 [cited 2023 Nov 15]. Available from: https://www.degruyter.com/document/doi/10.1515/biol-2022-0652/html
   Google Scholar
• Buckarma EH, Werneburg NW, Conboy CB, et al. The YAP-interacting phosphatase SHP2 can regulate transcriptional coactivity and modulate sensitivity to chemotherapy in cholangiocarcinoma. Mol Cancer Res MCR. 2020;18:1574–1588. doi: 10.1158/1541-7786.MCR-20-0165
   PubMed Web of Science ®Google Scholar
• Abou-Alfa GK, Bibeau K, Schultz N, et al. Effect of FGFR2 alterations on overall and progression-free survival in patients receiving systemic therapy for Intrahepatic Cholangiocarcinoma. Target Oncol [Internet]. 2022 [cited 2022 Sep 21]; Available from];17(5):517–527. doi: 10.1007/s11523-022-00906-w
   PubMed Web of Science ®Google Scholar
• Brandi G, Deiana C, Galvani L, et al. Are FGFR and IDH1-2 alterations a positive prognostic factor in intrahepatic cholangiocarcinoma? An unresolved issue. Front Oncol. 2023;13:1137510. doi: 10.3389/fonc.2023.1137510
   PubMed Web of Science ®Google Scholar
• Kim H, Kim JY, Park KU. Clinical implications of BRCA mutations in advanced biliary tract cancer. Oncology. 2023;101:41–48. doi: 10.1159/000527525
   PubMed Web of Science ®Google Scholar
• Mao Y, Huang X, Shuang Z, et al. PARP inhibitor olaparib sensitizes cholangiocarcinoma cells to radiation. Cancer Med. 2018;7(4):1285–1296. doi: 10.1002/cam4.1318
   PubMed Web of Science ®Google Scholar
• Banales JM, Cardinale V, Carpino G, et al. Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Nat Rev Gastroenterol Hepatol. 2016;13:261–280. doi: 10.1038/nrgastro.2016.51
   PubMed Web of Science ®Google Scholar
• Yu Y, Zhang M, Wang N, et al. Epigenetic silencing of tumor suppressor gene CDKN1A by oncogenic long non-coding RNA SNHG1 in cholangiocarcinoma. Cell Death Dis. 2018;9:746. doi: 10.1038/s41419-018-0768-6
   PubMed Web of Science ®Google Scholar
• Sittithumcharee G, Suppramote O, Vaeteewoottacharn K, et al. Dependency of cholangiocarcinoma on cyclin D-Dependent kinase activity. Hepatology. 2019;70:1614–1630. doi: 10.1002/hep.30704
   PubMed Web of Science ®Google Scholar
• Puik JR, Meijer LL, Le Large TY, et al. miRNA profiling for diagnosis, prognosis and stratification of cancer treatment in cholangiocarcinoma. Pharmacogenomics. 2017;18:1343–1358. doi: 10.2217/pgs-2017-0010
   PubMed Web of Science ®Google Scholar
• Meng F, Henson R, Lang M, et al. Involvement of human micro-RNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines. Gastroenterology. 2006;130:2113–2129. doi: 10.1053/j.gastro.2006.02.057
   PubMed Web of Science ®Google Scholar
• Toyota Y, Iwama H, Kato K, et al. Mechanism of gemcitabine-induced suppression of human cholangiocellular carcinoma cell growth. Int J Oncol. 2015;47:1293–1302. doi: 10.3892/ijo.2015.3118
   PubMed Web of Science ®Google Scholar
• Carotenuto P, Hedayat S, Fassan M, et al. Modulation of biliary cancer chemo-resistance through MicroRNA-mediated rewiring of the expansion of CD133+ cells. Hepatology. 2020;72:982–996. doi: 10.1002/hep.31094
   PubMed Web of Science ®Google Scholar
• Toledo B, Picon-Ruiz M, Marchal JA, et al. Dual role of fibroblasts educated by tumour in cancer behavior and therapeutic perspectives. Int J Mol Sci. 2022;23:15576.
   PubMed Web of Science ®Google Scholar
• Fabris L, Sato K, Alpini G, et al. The tumor microenvironment in cholangiocarcinoma progression. Hepatology. 2021;73:75–85. doi: 10.1002/hep.31410
   PubMed Web of Science ®Google Scholar
• Obata T, Tsutsumi K, Ueta E, et al. MicroRNA-451a inhibits gemcitabine-refractory biliary tract cancer progression by suppressing the MIF-mediated PI3K/AKT pathway. Mol Ther Nucleic Acids. 2023;34:102054. doi: 10.1016/j.omtn.2023.102054
   PubMedGoogle Scholar
• Yang C, Xu M, Shen H-J, et al. Potential biomarkers for sensitivity of gallbladder cancer cells to gemcitabine. Int J Clin Exp Pathol. 2014;7:521–528.
   PubMed Web of Science ®Google Scholar
• Okumura Y, Noda T, Eguchi H, et al. Hypoxia-induced PLOD2 is a key regulator in Epithelial-Mesenchymal transition and chemoresistance in biliary tract cancer. Ann Surg Oncol. 2018;25:3728–3737. doi: 10.1245/s10434-018-6670-8
   PubMed Web of Science ®Google Scholar
• Wang S, Zheng Y, Yang F, et al. The molecular biology of pancreatic adenocarcinoma: translational challenges and clinical perspectives. Signal Transduct Target Ther. 2021;6:1–23. doi: 10.1038/s41392-021-00659-4
   PubMed Web of Science ®Google Scholar
• Halbrook CJ, Lyssiotis CA, Pasca di Magliano M, et al. Pancreatic cancer: advances and challenges. Cell. 2023;186:1729–1754. doi: 10.1016/j.cell.2023.02.014
   PubMed Web of Science ®Google Scholar
• Garrido-Laguna I, Hidalgo M. Pancreatic cancer: from state-of-the-art treatments to promising novel therapies. Nat Rev Clin Oncol. 2015;12:319–334. doi: 10.1038/nrclinonc.2015.53
   PubMed Web of Science ®Google Scholar
• Fedele C, Ran H, Diskin B, et al. SHP2 inhibition prevents adaptive resistance to MEK inhibitors in multiple cancer models. Cancer Discov. 2018;8:1237–1249. doi: 10.1158/2159-8290.CD-18-0444
   PubMed Web of Science ®Google Scholar
• Ardalan B, Azqueta JI, England J, et al. Potential benefit of treatment with MEK inhibitors and chemotherapy in BRAF-mutated KRAS wild-type pancreatic ductal adenocarcinoma patients: a case report. Mol Case Stud. 2021;7:a006108. doi: 10.1101/mcs.a006108
   Google Scholar
• Strickler JH, Satake H, George TJ, et al. Sotorasib in KRAS p.G12C–mutated advanced pancreatic cancer. N Engl J Med. 2023;388:33–43. doi: 10.1056/NEJMoa2208470
   PubMed Web of Science ®Google Scholar
• Pan M, Jiang C, Zhang Z, et al. TP53 gain-of-function and non–gain-of-Function mutations are associated with differential prognosis in advanced pancreatic ductal adenocarcinoma. JCO Precis Oncol. 2023;e2200570. doi: 10.1200/PO.22.00570
   PubMedGoogle Scholar
• Rosen MN, Goodwin RA, Vickers MM. BRCA mutated pancreatic cancer: a change is coming. World J Gastroenterol. 2021;27:1943–1958. doi: 10.3748/wjg.v27.i17.1943
   PubMed Web of Science ®Google Scholar
• Wong W, Raufi AG, Safyan RA, et al. BRCA mutations in pancreas cancer: spectrum, current management, challenges and future prospects. Cancer Manag Res. 2020;12:2731–2742. doi: 10.2147/CMAR.S211151
   PubMed Web of Science ®Google Scholar
• Chen C-C, Kass EM, Yen W-F, et al. ATM loss leads to synthetic lethality in BRCA1 BRCT mutant mice associated with exacerbated defects in homology-directed repair. Proc Natl Acad Sci, USA. 2017;114(29):7665–7670. doi: 10.1073/pnas.1706392114
   PubMed Web of Science ®Google Scholar
• Shoucair S, Baker AR, Yu J. Germline variants in DNA damage repair genes: an emerging role in the era of precision medicine in pancreatic adenocarcinoma. Ann Gastroenterol Surg. 2022;6(1):7–16. doi: 10.1002/ags3.12514
   PubMed Web of Science ®Google Scholar
• Blair AB, Groot VP, Gemenetzis G, et al. BRCA1/BRCA2Germline mutation carriers and sporadic pancreatic ductal adenocarcinoma. J Am Coll Surg. 2018;226(4):630. doi: 10.1016/j.jamcollsurg.2017.12.021
   PubMed Web of Science ®Google Scholar
• Park W, Chen J, Chou JF, et al. Genomic methods identify homologous recombination deficiency in pancreas adenocarcinoma and optimize treatment selection. Clin Cancer Res. 2020;26(13):3239–3247. doi: 10.1158/1078-0432.CCR-20-0418
   PubMed Web of Science ®Google Scholar
• O’Reilly EM, Lee JW, Zalupski M, et al. Randomized, multicenter, phase II trial of gemcitabine and cisplatin with or without veliparib in patients with pancreas adenocarcinoma and a Germline BRCA/PALB2 Mutation. J Clin Oncol. 2020;38:1378–1388. doi: 10.1200/JCO.19.02931
   PubMed Web of Science ®Google Scholar
• Baylin SB, Jones PA. Epigenetic determinants of cancer. Cold Spring Harb Perspect Biol. 2016;8:a019505. doi: 10.1101/cshperspect.a019505
   PubMed Web of Science ®Google Scholar
• Wang SS, Xu J, Ji KY, et al. Epigenetic alterations in pancreatic cancer metastasis. Biomolecules. 2021;11:1082. doi: 10.3390/biom11081082
   PubMed Web of Science ®Google Scholar
• Kurdistani SK, Tavazoie S, Grunstein M. Mapping global histone acetylation patterns to gene expression. Cell. 2004;117:721–733. doi: 10.1016/j.cell.2004.05.023
   PubMed Web of Science ®Google Scholar
• Borchert GM, Lanier W, Davidson BL. RNA polymerase III transcribes human microRnas. Nat Struct Mol Biol. 2006;13:1097–1101. doi: 10.1038/nsmb1167
   PubMed Web of Science ®Google Scholar
• Pillai RS, Bhattacharyya SN, Filipowicz W. Repression of protein synthesis by miRnas: how many mechanisms? Trends Cell Biol. 2007;17(3):118–126. doi: 10.1016/j.tcb.2006.12.007
   PubMed Web of Science ®Google Scholar
• Hong TH, Park IY. MicroRNA expression profiling of diagnostic needle aspirates from surgical pancreatic cancer specimens. Ann Surg Treat Res. 2014;87:290–297. doi: 10.4174/astr.2014.87.6.290
   PubMed Web of Science ®Google Scholar
• Hampton T. MicroRNAs linked to pancreatic cancer. JAMA. 2007;297:937.
   PubMed Web of Science ®Google Scholar
• Ali A, Jamieson NB, Khan IN, et al. Prognostic implications of microRNA-21 overexpression in pancreatic ductal adenocarcinoma: an international multicenter study of 686 patients. Am J Cancer Res. 2022;12:5668–5683.
   PubMed Web of Science ®Google Scholar
• Frampton AE, Castellano L, Colombo T, et al. Integrated molecular analysis to investigate the role of microRnas in pancreatic tumour growth and progression. Lancet Lond Engl. 2015;385(Suppl 1):S37. doi: 10.1016/S0140-6736(15)60352-X
   PubMedGoogle Scholar
• Giovannetti E, Funel N, Peters GJ, et al. MicroRNA-21 in pancreatic cancer: correlation with clinical outcome and pharmacologic aspects underlying its role in the modulation of gemcitabine activity. Cancer Res. 2010;70:4528–4538. doi: 10.1158/0008-5472.CAN-09-4467
   PubMed Web of Science ®Google Scholar
• Vahabi M, Dehni B, Antomás I, et al. Targeting miRNA and using miRNA as potential therapeutic options to bypass resistance in pancreatic ductal adenocarcinoma. Cancer Metastasis Rev. 2023;42:725–740. doi: 10.1007/s10555-023-10127-w
   PubMed Web of Science ®Google Scholar
• Mittal V. Epithelial mesenchymal transition in tumor metastasis. Annu Rev Pathol. 2018;13:395–412. doi: 10.1146/annurev-pathol-020117-043854
   PubMed Web of Science ®Google Scholar
• El Amrani M, Corfiotti F, Corvaisier M, et al. Gemcitabine-induced epithelial-mesenchymal transition-like changes sustain chemoresistance of pancreatic cancer cells of mesenchymal-like phenotype. Mol Carcinog. 2019;58:1985–1997. doi: 10.1002/mc.23090
   PubMed Web of Science ®Google Scholar
• Kuwada K, Kagawa S, Yoshida R, et al. The epithelial-to-mesenchymal transition induced by tumor-associated macrophages confers chemoresistance in peritoneally disseminated pancreatic cancer. J Exp Clin Cancer Res. 2018;37:307. doi: 10.1186/s13046-018-0981-2
   PubMed Web of Science ®Google Scholar
• Hwang JS, Lai TH, Ahmed M, et al. Regulation of TGF-β1-induced EMT by autophagy-dependent energy metabolism in cancer cells. Cancers (Basel). 2022;14:4845. doi: 10.3390/cancers14194845
   PubMed Web of Science ®Google Scholar
• Izumchenko E, Chang X, Michailidi C, et al. The TGFβ–miR200–MIG6 pathway orchestrates the EMT-Associated kinase switch that induces resistance to EGFR inhibitors. Cancer Res. 2014;74:3995–4005. doi: 10.1158/0008-5472.CAN-14-0110
   PubMed Web of Science ®Google Scholar
• Sanomachi T, Suzuki S, Togashi K, et al. Brexpiprazole reduces survivin and reverses EGFR tyrosine kinase inhibitor resistance in lung and pancreatic cancer. Anticancer Res. 2019;39:4817–4828. doi: 10.21873/anticanres.13667
   PubMed Web of Science ®Google Scholar
• Zhao X, Yang Y, Yu H, et al. Polydatin inhibits ZEB1-invoked epithelial-mesenchymal transition in fructose-induced liver fibrosis. J Cell Mol Med. 2020;24:13208–13222. doi: 10.1111/jcmm.15933
   PubMed Web of Science ®Google Scholar
• Melchionna R, Iapicca P, Di Modugno F, et al. The pattern of hMENA isoforms is regulated by TGF-β1 in pancreatic cancer and may predict patient outcome. Oncoimmunology. 2016;5:e1221556. doi: 10.1080/2162402X.2016.1221556
   PubMed Web of Science ®Google Scholar
• Randazzo O, Papini F, Mantini G, et al. “Open Sesame?”: biomarker status of the human equilibrative nucleoside transporter-1 and molecular mechanisms influencing its expression and activity in the uptake and cytotoxicity of gemcitabine in pancreatic cancer. Cancers (Basel). 2020;12:3206. doi: 10.3390/cancers12113206
   PubMed Web of Science ®Google Scholar
• Toledo B, González-Titos A, Hernández-Camarero P, et al. A Brief Review on chemoresistance; targeting cancer stem cells as an alternative approach. Int J Mol Sci. 2023;24:4487. doi: 10.3390/ijms24054487
   PubMed Web of Science ®Google Scholar
• Wang C, Lin W, Playa H, et al. Dipyridamole analogs as pharmacological inhibitors of equilibrative nucleoside transporters. Identification of novel potent and selective inhibitors of the adenosine transporter function of human equilibrative nucleoside transporter 4 (hENT4). Biochem Pharmacol. 2013;86:1531–1540. doi: 10.1016/j.bcp.2013.08.063
   PubMed Web of Science ®Google Scholar
• Farrell JJ, Elsaleh H, Garcia M, et al. Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer. Gastroenterology. 2009;136:187–195. doi: 10.1053/j.gastro.2008.09.067
   PubMed Web of Science ®Google Scholar
• Greenhalf W, Ghaneh P, Neoptolemos JP, et al. Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial. JNCI J Natl Cancer Inst. 2014;106:djt347. doi: 10.1093/jnci/djt347
   Web of Science ®Google Scholar
• Hioki M, Shimada T, Yuan T, et al. Contribution of equilibrative nucleoside transporters 1 and 2 to gemcitabine uptake in pancreatic cancer cells. Biopharm Drug Dispos. 2018;39:256–264. doi: 10.1002/bdd.2131
   PubMed Web of Science ®Google Scholar
• Paproski RJ, Young JD, Cass CE. Predicting gemcitabine transport and toxicity in human pancreatic cancer cell lines with the positron emission tomography tracer 3′-deoxy-3′-fluorothymidine. Biochem Pharmacol. 2010;79:587–595. doi: 10.1016/j.bcp.2009.09.025
   PubMed Web of Science ®Google Scholar
• Lockhart AC, Tirona RG, Kim RB. Pharmacogenetics of ATP-binding cassette transporters in cancer and chemotherapy. Mol Cancer Ther. 2003;2:685–698.
   PubMed Web of Science ®Google Scholar
• Mathijssen RHJ, Marsh S, Karlsson MO, et al. Irinotecan pathway genotype analysis to predict pharmacokinetics. Clin Cancer Res Off J Am Assoc Cancer Res. 2003;9:3246–3253.
   PubMed Web of Science ®Google Scholar
• Chen M, Xue X, Wang F, et al. Expression and promoter methylation analysis of ATP-binding cassette genes in pancreatic cancer. Oncol Rep. 2012;27:265–269. doi: 10.3892/or.2011.1475
   PubMed Web of Science ®Google Scholar
• Yao L, Gu J, Mao Y, et al. Dynamic quantitative detection of ABC transporter family promoter methylation by MS‑HRM for predicting MDR in pancreatic cancer. Oncol Lett. 2018;15:5602–5610. doi: 10.3892/ol.2018.8041
   PubMed Web of Science ®Google Scholar
• Yada E, Kasajima R, Niida A, et al. Possible role of cytochrome P450 1B1 in the mechanism of gemcitabine resistance in pancreatic cancer. Biomedicines. 2021;9:1396. doi: 10.3390/biomedicines9101396
   PubMed Web of Science ®Google Scholar
• Leskelä S, Jara C, Leandro-García LJ, et al. Polymorphisms in cytochromes P450 2C8 and 3A5 are associated with paclitaxel neurotoxicity. Pharmacogenomics J. 2011;11:121–129. doi: 10.1038/tpj.2010.13
   PubMed Web of Science ®Google Scholar
• Bergonzini C, Gregori A, Hagens TMS, et al. ABCB1 overexpression through locus amplification represents an actionable target to combat paclitaxel resistance in pancreatic cancer cells [internet].bioRxiv; 2023 [cited 2024 Jan 26]. p. 2023.05.30.542412. Available from: https://www.biorxiv.org/content/10.1101/2023.05.30.542412v1
   Google Scholar
• Neuzillet C, Tijeras-Raballand A, Cros J, et al. Stromal expression of SPARC in pancreatic adenocarcinoma. Cancer Metastasis Rev. 2013;32:585–602. doi: 10.1007/s10555-013-9439-3
   PubMed Web of Science ®Google Scholar
• Von Hoff DD, Ramanathan RK, Borad MJ, et al. Gemcitabine plus nab-Paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J Clin Oncol. 2011;29(34):4548–4554. doi: 10.1200/JCO.2011.36.5742
   PubMed Web of Science ®Google Scholar
• Tuveson DA Data from nab-paclitaxel potentiates gemcitabine activity by reducing cytidine deaminase levels in a mouse Model of pancreatic cancer. 2023 [cited 2023 Nov 15]. Available from: https://aacr.figshare.com/collections/Data_from_i_nab_i_-Paclitaxel_Potentiates_Gemcitabine_Activity_by_Reducing_Cytidine_Deaminase_Levels_in_a_Mouse_Model_of_Pancreatic_Cancer/6546821
   Google Scholar
• Thomas D, Radhakrishnan P. Tumor-stromal crosstalk in pancreatic cancer and tissue fibrosis. Mol Cancer. 2019;18:14. doi: 10.1186/s12943-018-0927-5
   PubMed Web of Science ®Google Scholar
• Liot S, Balas J, Aubert A, et al. Stroma involvement in pancreatic ductal adenocarcinoma: an overview focusing on extracellular matrix proteins. Front Immunol. 2021;12 [cited 2023 Nov 15]. [Internet] Available from: https://www.frontiersin.org/articles/10.3389/fimmu.2021.612271
   Web of Science ®Google Scholar
• Liang C, Shi S, Meng Q, et al. Complex roles of the stroma in the intrinsic resistance to gemcitabine in pancreatic cancer: where we are and where we are going. Exp Mol Med. 2017;49:e406. doi: 10.1038/emm.2017.255
   PubMed Web of Science ®Google Scholar
• Rhim AD, Oberstein PE, Thomas DH, et al. Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma. Cancer Cell. 2014;25:735–747. doi: 10.1016/j.ccr.2014.04.021
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–674. doi: 10.1016/j.cell.2011.02.013
   PubMed Web of Science ®Google Scholar
• Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and metastasis. Nat Med. 2013;19:1423–1437. doi: 10.1038/nm.3394
   PubMed Web of Science ®Google Scholar
• Neesse A, Algül H, Tuveson DA, et al. Stromal biology and therapy in pancreatic cancer: a changing paradigm. Gut. 2015;64:1476–1484. doi: 10.1136/gutjnl-2015-309304
   PubMed Web of Science ®Google Scholar
• Grasso C, Jansen G, Giovannetti E. Drug resistance in pancreatic cancer: impact of altered energy metabolism. Crit Rev Oncol Hematol. 2017;114:139–152. doi: 10.1016/j.critrevonc.2017.03.026
   PubMed Web of Science ®Google Scholar
• Poklepovic AS, Fields EC, Bandyopadhyay D, et al. A phase 1 study of neoadjuvant chemotherapy followed by concurrent chemoradiation with gemcitabine, sorafenib, and vorinostat in pancreatic cancer. J Clin Oncol. 2021;39:e16268–e16268. doi: 10.1200/JCO.2021.39.15_suppl.e16268
   Google Scholar
• Algaze S, Hanna DL, Azad NS, et al. A phase Ib study of guadecitabine and durvalumab in patients with advanced hepatocellular carcinoma, pancreatic adenocarcinoma, and biliary cancers. J Clin Oncol. 2022;40:574–574. doi: 10.1200/JCO.2022.40.4_suppl.574
   Web of Science ®Google Scholar
• Barbato A, Piscopo F, Salati M, et al. Micro-RNA in cholangiocarcinoma: implications for diagnosis, prognosis, and therapy. J Mol Pathol. 2022;3:88–103. doi: 10.3390/jmp3020009
   Google Scholar
• Xie Y, Wang Y, Li J, et al. Cholangiocarcinoma therapy with nanoparticles that combine downregulation of MicroRNA-210 with inhibition of cancer cell invasiveness. Theranostics. 2018;8:4305. doi: 10.7150/thno.26506
   PubMed Web of Science ®Google Scholar
• Beg MS, Brenner AJ, Sachdev J, et al. Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors. Invest New Drugs. 2017;35:180–188. doi: 10.1007/s10637-016-0407-y
   PubMed Web of Science ®Google Scholar
• Yen W-C, Fischer MM, Axelrod F, et al. Targeting notch signaling with a Notch2/Notch3 antagonist (tarextumab) inhibits tumor growth and decreases tumor-initiating cell frequency. Clin Cancer Res. 2015;21:2084–2095. doi: 10.1158/1078-0432.CCR-14-2808
   PubMed Web of Science ®Google Scholar
• O’Reilly EM, Sahai V, Bendell JC, et al. Results of a randomized phase II trial of an anti-notch 2/3, tarextumab (OMP-59R5, TRXT, anti-Notch2/3), in combination with nab-paclitaxel and gemcitabine (nab-P+Gem) in patients (pts) with untreated metastatic pancreatic cancer (mPC). J Clin Oncol. 2017;35:279–279. doi: 10.1200/JCO.2017.35.4_suppl.279
   Web of Science ®Google Scholar
• Cook N, Basu B, Smith D-M, et al. A phase I trial of the ɣ-secretase inhibitor (GSI) MK-0752 in combination with gemcitabine in patients with pancreatic ductal adenocarcinoma (PDAC). J Clin Oncol. 2014;32:4116–4116. doi: 10.1200/jco.2014.32.15_suppl.4116
   Google Scholar
• Gulla A, Andriusaityte U, Zdanys GT, et al. The impact of epithelial–mesenchymal transition and metformin on pancreatic cancer chemoresistance: a pathway towards individualized therapy. Medicina (Mex). 2022;58:467. doi: 10.3390/medicina58040467
   Google Scholar
• Glabman RA, Choyke PL, Sato N. Cancer-associated fibroblasts: tumorigenicity and targeting for cancer therapy. Cancers (Basel). 2022;14:3906. doi: 10.3390/cancers14163906
   PubMedGoogle Scholar
• Albrengues J, Bertero T, Grasset E, et al. Epigenetic switch drives the conversion of fibroblasts into proinvasive cancer-associated fibroblasts. Nat Commun. 2015;6:10204. doi: 10.1038/ncomms10204
   PubMed Web of Science ®Google Scholar
• Gailhouste L, Liew LC, Hatada I, et al. Epigenetic reprogramming using 5-azacytidine promotes an anti-cancer response in pancreatic adenocarcinoma cells. Cell Death Dis. 2018;9:1–12. doi: 10.1038/s41419-018-0487-z
   PubMed Web of Science ®Google Scholar
• Safyan RA, Manji GA, Lee SM, et al. Phase 2 study of azacitidine (AZA) plus pembrolizumab (pembro) as second-line treatment in patients with advanced pancreatic ductal adenocarcinoma. J Clin Oncol. 2022;40:4158–4158. doi: 10.1200/JCO.2022.40.16_suppl.4158
   PubMed Web of Science ®Google Scholar
• Jimeno A, Weiss GJ, Miller WH, et al. Phase I study of the hedgehog pathway inhibitor IPI-926 in adult patients with solid tumors. Clin Cancer Res Off J Am Assoc Cancer Res. 2013;19:2766–2774. doi: 10.1158/1078-0432.CCR-12-3654
   PubMed Web of Science ®Google Scholar
• Hingorani SR, Zheng L, Bullock AJ, et al. HALO 202: randomized phase II study of PEGPH20 plus nab-Paclitaxel/Gemcitabine versus nab-Paclitaxel/Gemcitabine in patients with untreated, metastatic pancreatic ductal adenocarcinoma. J Clin Oncol. 2018;36:359–366. doi: 10.1200/JCO.2017.74.9564
   PubMed Web of Science ®Google Scholar
• Ramanathan RK, McDonough SL, Philip PA, et al. Phase IB/II randomized study of FOLFIRINOX plus pegylated recombinant human hyaluronidase versus FOLFIRINOX alone in patients with metastatic pancreatic adenocarcinoma: SWOG S1313. J Clin Oncol. 2019;37:1062–1069. doi: 10.1200/JCO.18.01295
   PubMed Web of Science ®Google Scholar
• Hurwitz HI, Uppal N, Wagner SA, et al. Randomized, double-blind, phase II study of ruxolitinib or placebo in combination with capecitabine in patients with metastatic pancreatic cancer for whom therapy with gemcitabine has failed. J Clin Oncol. 2015;33:4039–4047. doi: 10.1200/JCO.2015.61.4578
   PubMed Web of Science ®Google Scholar
• Hurwitz H, Van Cutsem E, Bendell JC, et al. Two randomized, placebo-controlled phase 3 studies of ruxolitinib (rux) + capecitabine (C) in patients (pts) with advanced/metastatic pancreatic cancer (mPC) after failure/intolerance of first-line chemotherapy: JANUS 1 (J1) and JANUS 2 (J2). J Clin Oncol. 2017;35:343–343. doi: 10.1200/JCO.2017.35.4_suppl.343
   PubMed Web of Science ®Google Scholar
• Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362:1273–1281. doi: 10.1056/NEJMoa0908721
   PubMed Web of Science ®Google Scholar
• Shroff RT, Javle MM, Xiao L, et al. Gemcitabine, cisplatin, and nab-paclitaxel for the treatment of advanced biliary tract cancers: a phase 2 clinical trial. JAMA Oncol. 2019;5:824–830. doi: 10.1001/jamaoncol.2019.0270
   PubMed Web of Science ®Google Scholar
• SWOG Cancer Research Network. A phase III randomized trial of Gemcitabine, cisplatin, and nab-paclitaxel versus Gemcitabine and cisplatin in newly diagnosed, advanced biliary tract cancers [Internet]. Report No.: NCT03768414. clinicaltrials.gov; 2023 [cited 2024 Jan 1]. Available from: https://clinicaltrials.gov/study/NCT03768414
   Google Scholar
• Lopes LF, Bacchi CE. Imatinib treatment for gastrointestinal stromal tumour (GIST). J Cell Mol Med. 2010;14:42–50. doi: 10.1111/j.1582-4934.2009.00983.x
   PubMed Web of Science ®Google Scholar
• Soria J-C, Ohe Y, Vansteenkiste J, et al. Osimertinib in untreated EGFR-mutated advanced non–small-cell lung cancer. N Engl J Med. 2018;378:113–125. doi: 10.1056/NEJMoa1713137
   PubMed Web of Science ®Google Scholar
• Sabnis AJ, Bivona TG. Principles of resistance to targeted cancer therapy: lessons from basic and translational cancer biology. Trends Mol Med. 2019;25:185–197. doi: 10.1016/j.molmed.2018.12.009
   PubMed Web of Science ®Google Scholar
• Yun C-H, Mengwasser KE, Toms AV, et al. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci. 2008;105:2070–2075. doi: 10.1073/pnas.0709662105
   PubMed Web of Science ®Google Scholar
• Poulikakos PI, Persaud Y, Janakiraman M, et al. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature. 2011;480:387–390. doi: 10.1038/nature10662
   PubMed Web of Science ®Google Scholar
• Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science. 2001;293:876–880. doi: 10.1126/science.1062538
   PubMed Web of Science ®Google Scholar
• Nazarian R, Shi H, Wang Q, et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature. 2010;468:973–977. doi: 10.1038/nature09626
   PubMed Web of Science ®Google Scholar
• Coleman N, Hong L, Zhang J, et al. Beyond epidermal growth factor receptor: MET amplification as a general resistance driver to targeted therapy in oncogene-driven non-small-cell lung cancer. ESMO Open. 2021;6:100319. doi: 10.1016/j.esmoop.2021.100319
   PubMed Web of Science ®Google Scholar
• De Las Rivas J, Brozovic A, Izraely S, et al. Cancer drug resistance induced by EMT: novel therapeutic strategies. Arch Toxicol. 2021;95:2279–2297. doi: 10.1007/s00204-021-03063-7
   PubMed Web of Science ®Google Scholar
• Yin X, Li Y, Wang H, et al. Small cell lung cancer transformation: From pathogenesis to treatment. Semin Cancer Biol. 2022;86:595–606. doi: 10.1016/j.semcancer.2022.03.006
   PubMed Web of Science ®Google Scholar
• Yang J, Antin P, Berx G, et al. Guidelines and definitions for research on epithelial–mesenchymal transition. Nat Rev Mol Cell Biol. 2020;21:341–352. doi: 10.1038/s41580-020-0237-9
   PubMed Web of Science ®Google Scholar
• Varghese AM, Patel JAA, Janjigian YY, et al. Non-invasive detection of acquired resistance to FGFR inhibition in patients with cholangiocarcinoma harboring FGFR2 alterations. JCO. 2019;37(15_suppl):4096–4096. doi: 10.1200/JCO.2019.37.15_suppl.4096
   Web of Science ®Google Scholar
• Goyal L, Saha SK, Liu LY, et al. Polyclonal secondary FGFR2 mutations drive acquired resistance to FGFR inhibition in patients with FGFR2 fusion–positive cholangiocarcinoma. Cancer Discov. 2017;7:252–263. doi: 10.1158/2159-8290.CD-16-1000
   PubMed Web of Science ®Google Scholar
• Silverman IM, Hollebecque A, Friboulet L, et al. Clinicogenomic analysis of FGFR2-rearranged cholangiocarcinoma identifies correlates of response and mechanisms of resistance to pemigatinib. Cancer Discov. 2021;11:326–339. doi: 10.1158/2159-8290.CD-20-0766
   PubMed Web of Science ®Google Scholar
• Lubner SJ, Mahoney MR, Kolesar JL, et al. Report of a multicenter phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: a phase II consortium study. J Clin Oncol. 2010;28:3491–3497. doi: 10.1200/JCO.2010.28.4075
   PubMed Web of Science ®Google Scholar
• Wu Q, Zhen Y, Shi L, et al. EGFR inhibition potentiates FGFR inhibitor therapy and overcomes resistance in FGFR2 fusion–positive cholangiocarcinoma. Cancer Discov. 2022;12:1378–1395. doi: 10.1158/2159-8290.CD-21-1168
   PubMed Web of Science ®Google Scholar
• Krook MA, Lenyo A, Wilberding M, et al. Efficacy of FGFR inhibitors and combination therapies for acquired resistance in FGFR2-fusion cholangiocarcinoma. Mol Cancer Ther. 2020;19:847–857. doi: 10.1158/1535-7163.MCT-19-0631
   PubMed Web of Science ®Google Scholar
• Vaquero J, Guedj N, Clapéron A, et al. Epithelial-mesenchymal transition in cholangiocarcinoma: from clinical evidence to regulatory networks. J Hepatol. 2017;66:424–441. doi: 10.1016/j.jhep.2016.09.010
   PubMed Web of Science ®Google Scholar
• Vaquero J, Lobe C, Tahraoui S, et al. The IGF2/IR/IGF1R Pathway in tumor Cells and myofibroblasts mediates resistance to EGFR inhibition in cholangiocarcinoma. Clin Cancer Res Off J Am Assoc Cancer Res. 2018;24:4282–4296. doi: 10.1158/1078-0432.CCR-17-3725
   PubMed Web of Science ®Google Scholar
• Hu ZI, O’Reilly EM. Therapeutic developments in pancreatic cancer. Nat Rev Gastroenterol Hepatol. 2023;21(1):7–24. doi: 10.1038/s41575-023-00840-w
   PubMed Web of Science ®Google Scholar
• Gurreri E, Genovese G, Perelli L, et al. KRAS-Dependency in pancreatic ductal adenocarcinoma: mechanisms of escaping in resistance to KRAS inhibitors and perspectives of therapy. Int J Mol Sci. 2023;24:9313.
   PubMed Web of Science ®Google Scholar
• Qin S, Bai Y, Wang Z, et al. Nimotuzumab combined with gemcitabine versus gemcitabine in K-RAS wild-type locally advanced or metastatic pancreatic cancer: a prospective, randomized-controlled, double-blinded, multicenter, and phase III clinical trial. J Clin Oncol. 2022;40:LBA4011–LBA4011. doi: 10.1200/JCO.2022.40.17_suppl.LBA4011
   Google Scholar
• Qian Y, Gong Y, Fan Z, et al. Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma. J Hematol OncolJ Hematol Oncol. 2020;13:130. doi: 10.1186/s13045-020-00958-3
   PubMed Web of Science ®Google Scholar
• Gout J, Perkhofer L, Morawe M, et al. Synergistic targeting and resistance to PARP inhibition in DNA damage repair-deficient pancreatic cancer. Gut. 2021;70:743–760. doi: 10.1136/gutjnl-2019-319970
   PubMed Web of Science ®Google Scholar
• Ettrich TJ, Schwerdel D, Dolnik A, et al. Genotyping of circulating tumor DNA in cholangiocarcinoma reveals diagnostic and prognostic information. Sci Rep. 2019;9:13261. doi: 10.1038/s41598-019-49860-0
   PubMed Web of Science ®Google Scholar
• Luchini C, Veronese N, Nottegar A, et al. Liquid biopsy as surrogate for tissue for molecular profiling in pancreatic cancer: a meta-analysis towards precision medicine. Cancers (Basel). 2019;11:1152. doi: 10.3390/cancers11081152
   PubMed Web of Science ®Google Scholar
• Gray JE, Okamoto I, Sriuranpong V, et al. Tissue and plasma EGFR mutation analysis in the FLAURA Trial: osimertinib versus Comparator EGFR Tyrosine Kinase Inhibitor as first-line treatment in patients with EGFR-Mutated advanced non–small cell lung cancer. Clin Cancer Res. 2019;25:6644–6652. doi: 10.1158/1078-0432.CCR-19-1126
   PubMed Web of Science ®Google Scholar
• Goyal L, Shi L, Liu LY, et al. TAS-120 overcomes resistance to ATP-competitive FGFR inhibitors in patients with FGFR2 fusion–positive Intrahepatic cholangiocarcinoma. Cancer Discov. 2019;9:1064–1079. doi: 10.1158/2159-8290.CD-19-0182
   PubMed Web of Science ®Google Scholar
• Pant S, Schuler MH, Iyer G, et al. Efficacy and safety of erdafitinib in adults with cholangiocarcinoma (CCA) with prespecified fibroblast growth factor receptor alterations (FGFRalt) in the phase 2 open-label, single-arm RAGNAR trial: expansion cohort results. J Clin Oncol. 2023;41:610–610. doi: 10.1200/JCO.2023.41.4_suppl.610
   Web of Science ®Google Scholar
• Javle MM, Fountzilas C, Li D, et al. Phase II study of FGFR1-3 inhibitor tinengotinib as monotherapy in patients with advanced or metastatic cholangiocarcinoma: Interim analysis. J Clin Oncol. 2023;41:539–539. doi: 10.1200/JCO.2023.41.4_suppl.539
   Web of Science ®Google Scholar
• Wang X, Allen S, Blake JF, et al. Identification of MRTX1133, a noncovalent, potent, and selective KRASG12D inhibitor. J Med Chem. 2022;65:3123–3133. doi: 10.1021/acs.jmedchem.1c01688
   PubMedGoogle Scholar
• Mirati Therapeutics Inc. A phase 1/2 multiple expansion cohort trial of MRTX1133 in patients with advanced solid tumors harboring a KRAS G12D mutation [internet]. Report No.: NCT05737706. clinicaltrials.gov; 2023 [cited 2023 Jan 1]. Available from: https://clinicaltrials.gov/study/NCT05737706
   Google Scholar
• Hofmann MH, Gmachl M, Ramharter J, et al. BI-3406, a potent and selective SOS1–KRAS interaction inhibitor, is effective in KRAS-Driven cancers through combined MEK inhibition. Cancer Discov. 2021;11:142–157. doi: 10.1158/2159-8290.CD-20-0142
   PubMed Web of Science ®Google Scholar
• Revolution medicines, Inc. A multicenter open-label study of RMC-6236 in patients with advanced solid tumors harboring specific mutations in RAS [internet]. Report No.: NCT05379985. clinicaltrials.gov; 2023 [cited 2023 Jan 1]. Available from: https://clinicaltrials.gov/study/NCT05379985
   Google Scholar
• Revolution Medicines, Inc. Phase 1/1b, multicenter, open-label, dose escalation and dose expansion study of RMC-6291 monotherapy in subjects with advanced KRASG12C mutant solid tumors [Internet]. Report No.: NCT05462717. clinicaltrials.gov; 2023 [cited 2023Jan 1]. Available from: https://clinicaltrials.gov/study/NCT05462717
   Google Scholar
• Brana I, Shapiro G, Johnson ML, et al. Initial results from a dose finding study of TNO155, a SHP2 inhibitor, in adults with advanced solid tumors. J Clin Oncol. 2021;39:3005–3005. doi: 10.1200/JCO.2021.39.15_suppl.3005
   Google Scholar
• Krishnan T, Roberts-Thomson R, Broadbridge V, et al. Targeting mutated KRAS genes to treat solid tumours. Mol Diagn Ther. 2022;26:39–49. doi: 10.1007/s40291-021-00564-0
   PubMed Web of Science ®Google Scholar
• Wallez Y, Dunlop CR, Johnson TI, et al. The ATR inhibitor AZD6738 synergizes with gemcitabine in vitro and in vivo to induce pancreatic ductal adenocarcinoma regression. Mol Cancer Ther. 2018;17:1670–1682. doi: 10.1158/1535-7163.MCT-18-0010
   PubMed Web of Science ®Google Scholar
• Prevo R, Fokas E, Reaper PM, et al. The novel ATR inhibitor VE-821 increases sensitivity of pancreatic cancer cells to radiation and chemotherapy. Cancer Biol Ther. 2012;13:1072–1081. doi: 10.4161/cbt.21093
   PubMed Web of Science ®Google Scholar
• Long GV, Stroyakovskiy D, Gogas H, et al. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet. 2015;386:444–451. doi: 10.1016/S0140-6736(15)60898-4
   PubMed Web of Science ®Google Scholar
• Brown WS, McDonald PC, Nemirovsky O, et al. Overcoming adaptive resistance to KRAS and MEK inhibitors by Co-targeting mTORC1/2 complexes in pancreatic cancer. Cell Rep Med [Internet]. 2020;1 [cited 2023 Oct 16]. Available from: https://www.cell.com/cell-reports-medicine/abstract/S2666-3791(20)30173-7
   Google Scholar
• Bannoura SF, Uddin M, Nagasaka M, et al. Targeting KRAS in pancreatic cancer: new drugs on the horizon. Cancer Metastasis Rev. 2021;40:819–835. doi: 10.1007/s10555-021-09990-2
   PubMed Web of Science ®Google Scholar
• LoRusso P, Fakih M, FYFLD V, et al. 561P phase ib study of ribociclib (R) + trametinib (T) in patients (pts) with metastatic/advanced solid tumours. Ann Oncol. 2020;31:S484. doi: 10.1016/j.annonc.2020.08.675
   Google Scholar
• Wang J, Zhao J, Zhong J, et al. 653O glecirasib (KRAS G12C inhibitor) in combination with JAB-3312 (SHP2 inhibitor) in patients with KRAS p.G12C mutated solid tumors. Ann Oncol. 2023;34:S459. doi: 10.1016/j.annonc.2023.09.1839
   Google Scholar
• BU C, ZHAO L, WANG L, et al. mTORC2 promotes pancreatic cancer progression and parp inhibitor resistance. Oncol Res. 31:495–503. doi: 10.32604/or.2023.029309
   PubMed Web of Science ®Google Scholar
• Rose M, Burgess JT, O’Byrne K, et al. PARP inhibitors: clinical relevance, mechanisms of action and tumor resistance. Front Cell Dev Biol. 2020;8:564601. doi: 10.3389/fcell.2020.564601
   PubMed Web of Science ®Google Scholar
• Revythis A, Limbu A, Mikropoulos C, et al. Recent insights into PARP and immuno-checkpoint inhibitors in Epithelial ovarian cancer. Int J Environ Res Public Health. 2022;19:8577. doi: 10.3390/ijerph19148577
   PubMed Web of Science ®Google Scholar
• Reiss KA, Mick R, Teitelbaum U, et al. Niraparib plus nivolumab or niraparib plus ipilimumab in patients with platinum-sensitive advanced pancreatic cancer: a randomised, phase 1b/2 trial. Lancet Oncol. 2022;23:1009–1020. doi: 10.1016/S1470-2045(22)00369-2
   PubMed Web of Science ®Google Scholar
• Corrie PG. A phase II study combining pembrolizumab with olaparib in metastatic pancreatic adenocarcinoma (PDA) patients with high Tumour Mutation Burden [internet]. Report No.: NCT05093231. clinicaltrials.gov; 2021 [cited 2024 Jan 1]. Available from: https://clinicaltrials.gov/study/NCT05093231
   Google Scholar
• National Cancer Institute (NCI). Randomized phase II clinical trial of olaparib + pembrolizumab vs. Olaparib alone as maintenance therapy in metastatic pancreatic cancer patients with germline BRCA1 or BRCA2 mutations [internet]. Report No.: NCT04548752. clinicaltrials.gov; 2024 [cited 2024 Jan 1]. Available from: https://clinicaltrials.gov/study/NCT04548752
   Google Scholar
• Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. Multi-agent Low Dose Chemotherapy (gemcitabine, Nab-paclitaxel, capecitabine, cisplatin, Irinotecan) followed by maintenance olaparib and Pembrolizumab in untreated metastatic pancreatic ductal adenocarcinoma [internet]. Report No.: NCT04753879. clinicaltrials.gov; 2023 [cited 2023 Jan 1]. Available from: https://clinicaltrials.gov/study/NCT04753879
   Google Scholar
• Mayo Clinic. Phase II study of Niraparib and TSR-042 in Patients with Germline or Somatic BRCA1/2 and PALB2-Related pancreatic cancer [internet]. Report No.: NCT04493060. clinicaltrials.gov; 2023 [cited 2023 Jan 1]. Available from: https://clinicaltrials.gov/study/NCT04493060
   Google Scholar
• Servier Bio-Innovation LLC. A phase 1/2, Safety Lead-in and dose expansion, open-label, multicenter trial investigating the Safety, tolerability, and preliminary activity of Ivosidenib in combination with nivolumab and Ipilimumab in Previously treated subjects with nonresectable or metastatic cholangiocarcinoma with an IDH1 Mutation [internet]. Report No.: NCT05921760.clinicaltrials.gov; 2023 [cited 2024 Jan 1]. Available from: https://clinicaltrials.gov/study/NCT05921760
   Google Scholar
• University Health Network, Toronto. A phase II study of Olaparib and durvalumab (MEDI 4736) in patients with IDH-Mutated solid tumors [internet]. Report No.: NCT03991832. clinicaltrials.gov; 2023 [cited 2024 Jan 1]. Available from: https://clinicaltrials.gov/study/NCT03991832
   Google Scholar
• Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018;359:1350–1355. doi: 10.1126/science.aar4060
   PubMed Web of Science ®Google Scholar
• Said SS, Ibrahim WN. Cancer resistance to immunotherapy: comprehensive insights with future perspectives. Pharmaceutics. 2023;15:1143. doi: 10.3390/pharmaceutics15041143
   PubMed Web of Science ®Google Scholar
• Schmiechen ZC, Stromnes IM. Mechanisms governing immunotherapy resistance in pancreatic ductal adenocarcinoma. Front Immunol [Internet]. 2021 [cited 2023 Oct 20];11. doi: 10.3389/fimmu.2020.613815
   PubMed Web of Science ®Google Scholar
• Yoon JH, Jung Y-J, Moon S-H. Immunotherapy for pancreatic cancer. World J Clin Cases. 2021;9:2969–2982. doi: 10.12998/wjcc.v9.i13.2969
   PubMed Web of Science ®Google Scholar
• Nakamura H, Arai Y, Totoki Y, et al. Genomic spectra of biliary tract cancer. Nat Genet. 2015;47:1003–1010. doi: 10.1038/ng.3375
   PubMed Web of Science ®Google Scholar
• Job S, Rapoud D, Dos Santos A, et al. Identification of four immune subtypes characterized by distinct composition and functions of tumor microenvironment in intrahepatic cholangiocarcinoma. Hepatology. 2020;72:965. doi: 10.1002/hep.31092
   PubMed Web of Science ®Google Scholar
• Lo JH, Agarwal R, Goff LW, et al. Immunotherapy in biliary tract cancers: current standard-of-care and emerging strategies. Cancers (Basel). 2023;15:3312. doi: 10.3390/cancers15133312
   PubMed Web of Science ®Google Scholar
• Goeppert B, Frauenschuh L, Zucknick M, et al. Major histocompatibility complex class I expression impacts on patient survival and type and density of immune cells in biliary tract cancer. Br J Cancer. 2015;113:1343–1349. doi: 10.1038/bjc.2015.337
   PubMed Web of Science ®Google Scholar
• Amankulor NM, Kim Y, Arora S, et al. Mutant IDH1 regulates the tumor-associated immune system in gliomas. Genes Dev. 2017;31:774–786. doi: 10.1101/gad.294991.116
   PubMed Web of Science ®Google Scholar
• Ruan R, Li L, Li X, et al. Unleashing the potential of combining FGFR inhibitor and immune checkpoint blockade for FGF/FGFR signaling in tumor microenvironment. Mol Cancer. 2023;22:60. doi: 10.1186/s12943-023-01761-7
   PubMed Web of Science ®Google Scholar
• Le DT, Durham JN, Smith KN, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017;357:409–413. doi: 10.1126/science.aan6733
   PubMed Web of Science ®Google Scholar
• Heumann T, Azad N. Next-generation immunotherapy for pancreatic ductal adenocarcinoma: navigating pathways of immune resistance. Cancer Metastasis Rev. 2021;40:837–862. doi: 10.1007/s10555-021-09981-3
   PubMed Web of Science ®Google Scholar
• Feig C, Gopinathan A, Neesse A, et al. The pancreas cancer microenvironment. Clin Cancer Res Off J Am Assoc Cancer Res. 2012;18:4266–4276. doi: 10.1158/1078-0432.CCR-11-3114
   PubMed Web of Science ®Google Scholar
• Knudsen ES, Vail P, Balaji U, et al. Stratification of pancreatic ductal adenocarcinoma: combinatorial genetic, stromal, and immunological markers. Clin Cancer Res Off J Am Assoc Cancer Res. 2017;23:4429. doi: 10.1158/1078-0432.CCR-17-0162
   PubMed Web of Science ®Google Scholar
• Piha-Paul SA, Oh D-Y, Ueno M, et al. Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: results from the KEYNOTE-158 and KEYNOTE-028 studies. Int J Cancer. 2020;147:2190–2198. doi: 10.1002/ijc.33013
   PubMed Web of Science ®Google Scholar
• Kim RD, Chung V, Alese OB, et al. A phase 2 multi-institutional study of nivolumab for patients with advanced refractory biliary tract cancer. JAMA Oncol. 2020;6:888–894. doi: 10.1001/jamaoncol.2020.0930
   PubMed Web of Science ®Google Scholar
• Terrero G, Datta J, Dennison J, et al. Ipilimumab/Nivolumab therapy in patients with metastatic pancreatic or biliary cancer with homologous recombination deficiency pathogenic germline variants. JAMA Oncol. 2022;8:938–940. doi: 10.1001/jamaoncol.2022.0611
   Web of Science ®Google Scholar
• Klein O, Kee D, Nagrial A, et al. Evaluation of combination nivolumab and ipilimumab immunotherapy in patients with advanced biliary tract cancers: subgroup analysis of a phase 2 nonrandomized clinical trial. JAMA Oncol. 2020;6:1405–1409. doi: 10.1001/jamaoncol.2020.2814
   PubMed Web of Science ®Google Scholar
• Doki Y, Ueno M, Hsu C-H, et al. Tolerability and efficacy of durvalumab, either as monotherapy or in combination with tremelimumab, in patients from Asia with advanced biliary tract, esophageal, or head-and-neck cancer. Cancer Med. 2022;11:2550–2560. doi: 10.1002/cam4.4593
   PubMed Web of Science ®Google Scholar
• Lin J, Yang X, Long J, et al. Pembrolizumab combined with lenvatinib as non-first-line therapy in patients with refractory biliary tract carcinoma. Hepatobiliary Surg Nutr. 2020;9:41424–41424. doi: 10.21037/hbsn-20-338
   Web of Science ®Google Scholar
• Cousin S, Cantarel C, Guegan J-P, et al. Regorafenib–avelumab combination in patients with biliary tract cancer (REGOMUNE): a single-arm, open-label, phase II trial. Eur J Cancer. 2022;162:161–169. doi: 10.1016/j.ejca.2021.11.012
   PubMed Web of Science ®Google Scholar
• Shi G-M, Huang X-Y, Wu D, et al. Toripalimab combined with lenvatinib and GEMOX is a promising regimen as first-line treatment for advanced intrahepatic cholangiocarcinoma: a single-center, single-arm, phase 2 study. Signal Transduct Target Ther. 2023;8:1–10. doi: 10.1038/s41392-023-01317-7
   PubMed Web of Science ®Google Scholar
• Guo Y, Feng K, Liu Y, et al. Phase I study of Chimeric Antigen Receptor–modified T cells in patients with EGFR-Positive advanced biliary tract cancers. Clin Cancer Res. 2018;24:1277–1286. doi: 10.1158/1078-0432.CCR-17-0432
   PubMed Web of Science ®Google Scholar
• Koido S, Homma S, Okamoto M, et al. Chemoimmunotherapy targeting Wilms’ tumor 1 (WT1)-specific cytotoxic T lymphocyte and helper T cell responses for patients with pancreatic cancer. Oncoimmunology. 2014;3:e958950. doi: 10.4161/21624011.2014.958950
   PubMed Web of Science ®Google Scholar
• Wang-Gillam A, Plambeck-Suess S, Goedegebuure P, et al. A phase I study of IMP321 and gemcitabine as the front-line therapy in patients with advanced pancreatic adenocarcinoma. Invest New Drugs. 2013;31:707–713. doi: 10.1007/s10637-012-9866-y
   PubMed Web of Science ®Google Scholar
• Bahary N, Wang-Gillam A, Haraldsdottir S, et al. Phase 2 trial of the IDO pathway inhibitor indoximod plus gemcitabine/nab-paclitaxel for the treatment of patients with metastatic pancreas cancer. J Clin Oncol. 2018;36:4015–4015. doi: 10.1200/JCO.2018.36.15_suppl.4015
   Google Scholar
• Marin-Acevedo JA, Dholaria B, Soyano AE, et al. Next generation of immune checkpoint therapy in cancer: new developments and challenges. J Hematol OncolJ Hematol Oncol. 2018;11:39. doi: 10.1186/s13045-018-0582-8
   PubMed Web of Science ®Google Scholar
• Rojas LA, Sethna Z, Soares KC, et al. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. Nature. 2023;618:144–150. doi: 10.1038/s41586-023-06063-y
   PubMed Web of Science ®Google Scholar
• Feng Q, Sun B, Xue T, et al. Advances in CAR T-cell therapy in bile duct, pancreatic, and gastric cancers. Front Immunol. 2022;13 [cited 2023 Oct 20]. [Internet] Available from: https://www.frontiersin.org/articles/10.3389/fimmu.2022.1025608
   Web of Science ®Google Scholar
• Leem G, Jang S-I, Cho J-H, et al. Safety and efficacy of allogeneic natural killer cells in combination with pembrolizumab in patients with chemotherapy-refractory biliary tract cancer: a multicenter open-label phase 1/2a trial. Cancers (Basel). 2022;14:4229. doi: 10.3390/cancers14174229
   PubMed Web of Science ®Google Scholar
• Elrakaybi A, Ruess DA, Lübbert M, et al. Epigenetics in Pancreatic Ductal Adenocarcinoma: Impact on Biology and Utilization in Diagnostics and Treatment. Cancers (Basel). 2022;14:5926. doi: 10.3390/cancers14235926
   PubMed Web of Science ®Google Scholar
• Wang L Capecitabine combined with lenvatinib and Tislelizumab as adjuvant treatment after resection in patients with biliary tract cancer: a single-arm, phase II study [internet]. Report No.: NCT05254847. clinicaltrials.gov; 2022 [cited 2024 Jan 1]. Available from: https://clinicaltrials.gov/study/NCT05254847
   Google Scholar
• Kuang M Adjuvant immunotherapy combined with chemoradiation for patients with high-risk reseCtable extrahepatic chOlangiocarcinoma and gallblaDder cancer: a phase II, multicenter, randomized controlled trial [Internet].Report No.: NCT04333927. clinicaltrials.gov; 2020 [cited 2024 Jan 1]. Available from: https://clinicaltrials.gov/study/NCT04333927
   Google Scholar
• Institut für klinische krebsforschung IKF GmbH at Krankenhaus Nordwest. A phase II study of immunotherapy with durvalumab and tremelimumab in combination with capecitabine or without capecitabine in adjuvant situation for biliary tract cancer [Internet]. Report No.: NCT05239169. clinicaltrials.gov; 2024 [cited 2024 Jan 1]. Available from: https://clinicaltrials.gov/study/NCT05239169
   Google Scholar
• Shanghai Zhongshan Hospital. A randomized controlled, multicenter, open-label, phase II clinical study of PD1 antibody (toripalimab) combined with GEMOX Chemotherapy and lenvatinib neoadjuvant treatment for resectable intrahepatic cholangiocarcinoma with high-risk recurrence factors [internet]. Report No.: NCT04506281. clinicaltrials.gov; 2020 [cited 2024 Jan 1]. Available from: https://clinicaltrials.gov/study/NCT04506281
   Google Scholar
• Chen W, Xu D, Liu Q, et al. Unraveling the heterogeneity of cholangiocarcinoma and identifying biomarkers and therapeutic strategies with single-cell sequencing technology. Biomed Pharmacother. 2023;162:114697. doi: 10.1016/j.biopha.2023.114697
   PubMed Web of Science ®Google Scholar
• Connor AA, Gallinger S. Pancreatic cancer evolution and heterogeneity: integrating omics and clinical data. Nat Rev Cancer. 2022;22:131–142. doi: 10.1038/s41568-021-00418-1
   PubMed Web of Science ®Google Scholar
• Mody K, Jain P, El-Refai SM, et al. Clinical, genomic, and transcriptomic data profiling of biliary tract cancer reveals subtype-specific immune signatures. JCO Precis Oncol. 2022;6:e2100510. doi: 10.1200/PO.21.00510
   PubMed Web of Science ®Google Scholar
• Parikh AR, Leshchiner I, Elagina L, et al. Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers. Nat Med. 2019;25:1415–1421. doi: 10.1038/s41591-019-0561-9
   PubMed Web of Science ®Google Scholar
• Pellecchia S, Viscido G, Franchini M, et al. Predicting drug response from single-cell expression profiles of tumours. BMC Med. 2023;21:476. doi: 10.1186/s12916-023-03182-1
   PubMed Web of Science ®Google Scholar
• Zhang J, Zhang H, Zhang L, et al. Single-Cell transcriptome identifies drug-resistance signature and immunosuppressive microenvironment in metastatic small cell lung cancer. Adv Genet Hoboken NJ. 2022;3:2100060. doi: 10.1002/ggn2.202100060
   PubMedGoogle Scholar
• Bueschbell B, Caniceiro AB, Suzano PMS, et al. Network biology and artificial intelligence drive the understanding of the multidrug resistance phenotype in cancer. Drug Resist Updat. 2022;60:100811. doi: 10.1016/j.drup.2022.100811
   PubMed Web of Science ®Google Scholar
• You Y, Lai X, Pan Y, et al. Artificial intelligence in cancer target identification and drug discovery. Signal Transduct Target Ther [Internet]. 2022;7 [cited 2023 Oct 30]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9090746/
   Google Scholar
• Patel SK, George B, Rai V. Artificial intelligence to decode cancer mechanism: beyond patient stratification for precision oncology. Front Pharmacol [Internet]. 2020 [cited 2023 Oct 30];11. doi: 10.3389/fphar.2020.01177
   Web of Science ®Google Scholar
• Hayashi H, Uemura N, Matsumura K, et al. Recent advances in artificial intelligence for pancreatic ductal adenocarcinoma. World J Gastroenterol. 2021;27:7480–7496. doi: 10.3748/wjg.v27.i43.7480
   PubMed Web of Science ®Google Scholar
• Applying artificial intelligence to big data in hepatopancreatic and biliary surgery: a scoping review. Artif Intell Surg. 2023;3:27–47. doi: 10.20517/ais.2022.39
   Google Scholar
• Beatty GL, Werba G, Lyssiotis CA, et al. The biological underpinnings of therapeutic resistance in pancreatic cancer. Genes Dev. 2021;35:940–962. doi: 10.1101/gad.348523.121
   PubMed Web of Science ®Google Scholar